DelSiTech Enters into an Exclusive Licensing Agreement with Optifye Therapeutics for the Development of a Controlled Release Ophthalmic Eye Drop Product

Corporate Breaking News

Home : DelSiTech Enters into an Exclusive Licensing Agreement with Optifye Therapeutics for the Development of a Controlled Release Ophthalmic Eye Drop Product

Mar 28 2022	DelSiTech Enters into an Exclusive Licensing Agreement with Optifye Therapeutics for the Development of a Controlled Release Ophthalmic Eye Drop Product
TURKU, Finland, March 28, 2022 /PRNewswire/ -- DelSiTech Ltd, the leading silica drug delivery technology company, based in Finland and Optifye Therapeutics AG, a Swiss-based pharmaceutical company focusing on the development and commercialization of treatments for ophthalmic indications,...


Source:https://www.prnewswire.com:443/news-releases/delsitech-enters-into-an-exclusive-licensing-agreement-with-optifye-therapeutics-for-the-development-of-a-controlled-release-ophthalmic-eye-drop-product-301510917.html

Related News
» Vela Diagnostics présente ses panels de séquençage des gènes du cancer ciblés (60 gènes) et complets (525 gènes) basés sur les NGS » Biden spokesperson tests positive for COVID-19 after trip